Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01488877 · ClinicalTrials.gov registry record · Phase 1
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01488877 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 6 participants.
The verdict
NCT01488877, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845 in this population.
Interventions
- DRUG Spironolactone
- OTHER placebo
- DRUG PF-03882845
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01488877
The ClinicalTrials.gov registry entry for NCT01488877 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Spironolactone is the first listed.
NCT01488877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01488877 about?
NCT01488877 is a clinical study titled "A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy". PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845 in this population.
What is the current status of trial NCT01488877?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2012-01. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01488877?
The interventions under investigation include: Spironolactone (DRUG), placebo (OTHER), PF-03882845 (DRUG).
Who is sponsoring clinical trial NCT01488877?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.